PT  - JOURNAL ARTICLE
AU  - Yang, Wan
AU  - Shaman, Jeffrey
TI  - COVID-19 pandemic dynamics in India and impact of the SARS-CoV-2 Delta (B.1.617.2) variant
AID  - 10.1101/2021.06.21.21259268
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.21.21259268
4099  - http://medrxiv.org/content/early/2021/06/25/2021.06.21.21259268.short
4100  - http://medrxiv.org/content/early/2021/06/25/2021.06.21.21259268.full
AB  - The Delta SARS-CoV-2 variant has spread quickly since first being identified. To better understand its epidemiological characteristics and impact, we utilize multiple datasets and comprehensive model-inference methods to reconstruct COVID-19 pandemic dynamics in India, where Delta first emerged. Using model-inference estimates from March 2020 to May 2021, we estimate the Delta variant can escape adaptive immunity induced by prior wildtype infection roughly half of the time and is around 60% more infectious than wildtype SARS-CoV-2. In addition, our analysis suggests that the recent case decline in India was likely due to implemented non-pharmaceutical interventions and weather conditions less conducive for SARS-CoV-2 transmission during March – May, rather than high population immunity. Model projections show infections could resurge as India enters its monsoon season, beginning June, if intervention measures are lifted prematurely.Competing Interest StatementJS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI.Funding StatementThis study was supported by the National Institute of Allergy and Infectious Diseases (AI145883 and AI163023), the National Science Foundation Rapid Response Research Program (RAPID; DMS-2027369) and a gift from the Morris-Singer Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available as described in the Data sources and processing section.